scholarly journals Involuntary outpatient commitment did not reduce hospital recidivism, though may for some patient subgroups

2000 ◽  
Vol 3 (2) ◽  
pp. 53-53
Author(s):  
R. O'Kearney
Keyword(s):  
Outpatient Commitment ◽  
Hospital Recidivism ◽  
Patient Subgroups

Evaluation of the New York City (Bellevue) Involuntary Outpatient Commitment Pilot Program

1999 ◽  
Author(s):  
Kim Hopper ◽  
Henry J. Steadman ◽  
Jeanne Dumont ◽  
David L. Shern ◽  
Marvin Swartz
Keyword(s):  
New York ◽  
New York City ◽  
York City ◽  
Pilot Program ◽  
Outpatient Commitment

Patterns of clozapine pharmacokinetics in patient subgroups with different body mass index

2020 ◽  
Author(s):  
M Kuzin ◽  
E Haen ◽  
B Bochon ◽  
K Endres ◽  
F Ridders ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Patient Subgroups

scholarly journals Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study

2021 ◽  
Vol 11 (8) ◽  
Author(s):  
Andrew Staron ◽  
Luke Zheng ◽  
Gheorghe Doros ◽  
Lawreen H. Connors ◽  
Lisa M. Mendelson ◽  
...  
Keyword(s):  
Standards Of Care ◽  
Al Amyloidosis ◽  
Unexpected Death ◽  
Related Factors ◽  
Term Survival ◽  
Natural History Study ◽  
Boston University ◽  
Disease Outcomes ◽  
Patient Subgroups ◽  
Over Time

AbstractThe recent decades have ushered in considerable advancements in the diagnosis and treatment of systemic light chain (AL) amyloidosis. As disease outcomes improve, AL amyloidosis-unrelated factors may impact mortality. In this study, we evaluated survival trends and primary causes of death among 2337 individuals with AL amyloidosis referred to the Boston University Amyloidosis Center. Outcomes were analyzed according to date of diagnosis: 1980-1989 (era 1), 1990-1999 (era 2), 2000-2009 (era 3), and 2010-2019 (era 4). Overall survival increased steadily with median values of 1.4, 2.6, 3.3, and 4.6 years for eras 1–4, respectively (P < 0.001). Six-month mortality decreased over time from 23% to 13%. Wide gaps in survival persisted amid patient subgroups; those with age at diagnosis ≥70 years had marginal improvements over time. Most deaths were attributable to disease-related factors, with cardiac failure (32%) and sudden unexpected death (23%) being the leading causes. AL amyloidosis-unrelated mortality increased across eras (from 3% to 16% of deaths) and with longer-term survival (29% of deaths occurring >10 years after diagnosis). Under changing standards of care, survival improved and early mortality declined over the last 40 years. These findings support a more optimistic outlook for patients with AL amyloidosis.

scholarly journals Determinants of therapeutic lag in multiple sclerosis

2021 ◽  
pp. 135245852098130
Author(s):  
Izanne Roos ◽  
Emmanuelle Leray ◽  
Federico Frascoli ◽  
Romain Casey ◽  
J William L Brown ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Expanded Disability Status Scale ◽  
Disability Progression ◽  
Delayed Onset ◽  
Disease Characteristics ◽  
Disability Status ◽  
Male Sex ◽  
Pre Treatment ◽  
Patient Subgroups

Background: A delayed onset of treatment effect, termed therapeutic lag, may influence the assessment of treatment response in some patient subgroups. Objectives: The objective of this study is to explore the associations of patient and disease characteristics with therapeutic lag on relapses and disability accumulation. Methods: Data from MSBase, a multinational multiple sclerosis (MS) registry, and OFSEP, the French MS registry, were used. Patients diagnosed with MS, minimum 1 year of exposure to MS treatment and 3 years of pre-treatment follow-up, were included in the analysis. Studied outcomes were incidence of relapses and disability accumulation. Therapeutic lag was calculated using an objective, validated method in subgroups stratified by patient and disease characteristics. Therapeutic lag under specific circumstances was then estimated in subgroups defined by combinations of clinical and demographic determinants. Results: High baseline disability scores, annualised relapse rate (ARR) ⩾ 1 and male sex were associated with longer therapeutic lag on disability progression in sufficiently populated groups: females with expanded disability status scale (EDSS) < 6 and ARR < 1 had mean lag of 26.6 weeks (95% CI = 18.2–34.9), males with EDSS < 6 and ARR < 1 31.0 weeks (95% CI = 25.3–36.8), females with EDSS < 6 and ARR ⩾ 1 44.8 weeks (95% CI = 24.5–65.1), and females with EDSS ⩾ 6 and ARR < 1 54.3 weeks (95% CI = 47.2–61.5). Conclusions: Pre-treatment EDSS and ARR are the most important determinants of therapeutic lag.

scholarly journals Similar glycaemic control and risk of hypoglycaemia with patient- versus physician-managed titration of insulin glargine 300 U/mL across subgroups of patients with T2DM: a post hoc analysis of ITAS

2021 ◽  
Author(s):  
Andrea Giaccari ◽  
R. C. Bonadonna ◽  
R. Buzzetti ◽  
G. Perseghin ◽  
D. Cucinotta ◽  
...  
Keyword(s):  
Glycaemic Control ◽  
Insulin Glargine ◽  
Patient Characteristics ◽  
Efficacy And Safety ◽  
Clinical Trial Registration ◽  
Post Hoc Analysis ◽  
Almost All ◽  
Antihyperglycaemic Drugs ◽  
Post Hoc ◽  
Patient Subgroups

Abstract Aims The Italian Titration Approach Study (ITAS) demonstrated comparable HbA1c reductions and similarly low hypoglycaemia risk at 6 months in poorly controlled, insulin-naïve adults with T2DM who initiated self- or physician-titrated insulin glargine 300 U/mL (Gla-300) in the absence of sulphonylurea/glinide. The association of patient characteristics with glycaemic and hypoglycaemic outcomes was assessed. Methods This post hoc analysis investigated whether baseline patient characteristics and previous antihyperglycaemic drugs were associated with HbA1c change and hypoglycaemia risk in patient- versus physician-managed Gla-300 titration. Results HbA1c change, incidence of hypoglycaemia (any type) and nocturnal rates were comparable between patient- and physician-managed arms in all subgroups. Hypoglycaemia rates across subgroups (0.03 to 3.52 events per patient-year) were generally as low as observed in the full ITAS population. Small increases in rates of 00:00–pre-breakfast and anytime hypoglycaemia were observed in the ≤ 10-year diabetes duration subgroup in the patient- versus physician-managed arm (heterogeneity of effect; p < 0.05). Conclusions Comparably fair glycaemic control and similarly low hypoglycaemia risk were achieved in almost all patient subgroups with patient- versus physician-led Gla-300 titration. These results reinforce efficacy and safety of Gla-300 self-titration across a range of phenotypes of insulin-naïve people with T2DM. Clinical trial registration EudraCT 2015-001167-39

Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial

2015 ◽  
Vol 9 (1) ◽  
pp. 65-71 ◽  
Author(s):  
Eliot A. Brinton ◽  
Uma Kher ◽  
Sukrut Shah ◽  
Christopher P. Cannon ◽  
Michael Davidson ◽  
...  
Keyword(s):  
Plasma Lipids ◽  
Specific Patient ◽  
Cetp Inhibition ◽  
Patient Subgroups

scholarly journals Observed Differences in Diagnostic Test Accuracy between Patient Subgroups: Is It Real or Due to Reference Standard Misclassification?

2007 ◽  
Vol 53 (10) ◽  
pp. 1725-1729 ◽  
Author(s):  
Corné Biesheuvel ◽  
Les Irwig ◽  
Patrick Bossuyt
Keyword(s):  
Clinical Practice ◽  
Diagnostic Test ◽  
Sensitivity And Specificity ◽  
Diagnostic Test Accuracy ◽  
Test Accuracy ◽  
Reference Standard ◽  
Target Condition ◽  
Test Sensitivity ◽  
The Past ◽  
Patient Subgroups

Abstract Before a new test is introduced in clinical practice, its accuracy should be assessed. In the past decade, researchers have put an increased emphasis on exploring differences in test sensitivity and specificity between patient subgroups. If the reference standard is imperfect and the prevalence of the target condition differs among subgroups, apparent differences in test sensitivity and specificity between subgroups may be caused by reference standard misclassification. We provide guidance on how to determine whether observed differences may be explained by reference standard misclassification. Such misclassification may be ascertained by examining how the apparent sensitivity and specificity change with the prevalence of the target condition in the subgroups.

Sign in / Sign up

Export Citation Format

Share Document